<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998399</url>
  </required_header>
  <id_info>
    <org_study_id>131908</org_study_id>
    <nct_id>NCT01998399</nct_id>
  </id_info>
  <brief_title>Ticagrelor in Severe Community Acquired Pneumonia</brief_title>
  <acronym>TCAP</acronym>
  <official_title>Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gordon Bernard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the drug ticagrelor will be an effective
      treatment for patients with severe community acquired pneumonia. The primary objective is to
      reduce all-cause mortality in the ticagrelor group compared to the placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment, unable to meet recruitment goals
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>death during 90 day study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shock Free Days</measure>
    <time_frame>15 days</time_frame>
    <description>Not requiring pressor support for hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality</measure>
    <time_frame>Throughout hospitalization (About 2 weeks)</time_frame>
    <description>Did the patient die during the hospitalization?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Free Days</measure>
    <time_frame>29 days</time_frame>
    <description>Number of days the patient is not in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>90 days</time_frame>
    <description>Did the patient develop a stroke during the 90 day study?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke, Myocardial Infarct, Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>number of participants that suffered stroke, myocardial infarct, mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>90 days</time_frame>
    <description>Did the patient have a myocardial infarction during the 90 day study?</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to Initiation of Unassisted Breathing</measure>
    <time_frame>29 days</time_frame>
    <description>Only in patients on mechanical ventilation and assuming patient achieves 48 consecutive hours of unassisted breathing</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for Re-instituting Assisted or Mechanical Ventilation After Achieving 48 Consecutive Hours of Unassisted Breathing or Comfort Care Chosen (Withdrawal of Support)</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Need for Dialysis</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>29 days</time_frame>
    <description>Includes ICU readmission if during same hospital stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>29 days</time_frame>
    <description>In days</description>
  </other_outcome>
  <other_outcome>
    <measure>Discharge Disposition</measure>
    <time_frame>90 days</time_frame>
    <description>(Home, other facility, with or without assisted ventilation)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Community Acquired Pneumonia, Severe</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients will have new &quot;severe&quot; CAP as defined by

        a. New (within 72 hours of hospital admission) radiographic finding consistent with
        pneumonia and admission or planned admission to an ICU for: i. Mechanical Ventilation
        (invasive or non-invasive) OR ii. Vasopressors (dobutamine and phosphodiesterase are not
        considered vasopressors for this criteria) OR iii. ICU admission due to severe respiratory
        distress or arterial desaturation. b. At least two of the following; i. recent increase in
        dyspnea ii. increased sputum production iii. change of character of sputum iv. White Blood
        Cells &gt; 12,000 or &lt; 4,000 cells/mm3 or &gt;10% bands v. Body temperature &gt;38ºC or &lt;36ºC (any
        route)

        Exclusion Criteria:

          1. More than 72 hours have passed since meeting required inclusion criteria.

          2. Development of pneumonia after 72 hours of current hospitalization.

          3. Underlying disease likely to cause mortality within 90 days of randomization.

          4. A resident in a hospital, not nursing home, within 30 days prior to development of
             pneumonia.

          5. Patients who are moribund (not expected to live for more than 48 hours).

          6. No consent/inability to obtain consent from patient or surrogate.

          7. Patient's physician is unwilling to have patient enter the study.

          8. Age less than 50 years.

          9. Pregnancy.

         10. Breast feeding.

         11. Underlying immunodeficiency (e.g. HIV, neutropenia, active hematologic malignancy,
             functional or anatomical asplenia and hypogammaglobulinemia).

         12. Patient, surrogate, or physician not committed to full support (exception: a patient
             will not be excluded if he/she will receive all supportive care except for attempts at
             resuscitation from cardiac arrest).

         13. Unable to receive or unlikely to absorb enteral study drug (e.g., patients with
             partial or complete mechanical bowel obstruction, intestinal ischemia, infarction, and
             short bowel syndrome).

         14. Hepatic impairment

             a. Child Pugh score &gt; 7 using data from outpatient setting

         15. Conditions that increase the risk of bleeding, e.g.:

               1. Surgery or the likely need for surgery during study, or evidence of active
                  bleeding postoperatively (ICU procedures such as line placement, tracheostomy and
                  chest tubes are not to be considered for this exclusion);

               2. A history of severe head trauma requiring hospitalization or intra-cranial
                  surgery within 3 months;

               3. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or
                  mass lesions of the central nervous system, hemorrhagic stroke or intracranial
                  hemorrhage, or congenital bleeding diathesis;

               4. Gastrointestinal bleeding within 6 weeks before the study unless a corrective
                  procedure has been performed;

               5. Recent trauma considered to increase the risk of bleeding.

         16. Chronic renal disease requiring renal replacement therapy.

         17. Creatinine &gt; 3 mg/dL.

         18. Platelet count &lt; 50,000 /mm3.

         19. Use of a P2Y12 inhibitor within the 3 months prior to randomization or physician
             intent to initiate one of the CYP3A inhibitors, e.g. ketoconazole, itraconazole,
             voriconazole, clarithromycin, nefazodone, ritonavir, atazanovir, saquinavir,
             nelfinavir, indinavir, or telithromycin.

         20. Use of CYP3A inducers, e.g. rifampin, phenytoin, carbamazepine and phenobarbital.

         21. Simvastatin or Lovastatin doses &gt; 40 mg per day.

         22. Digoxin use.

         23. Receiving aspirin and physician and/or patient unwilling to reduce aspirin dose to
             &lt;100 mg per day.

         24. Daily Non-steroidal anti-inflammatory drugs (NSAID) use as an outpatient (other than
             Aspirin (ASA) as above).

         25. Sick Sinus Syndrome, 2nd or 3rd degree heart block, bradycardia induced syncope -
             unless pacemaker in place.

         26. Otherwise unsuitable for participation in the opinion of the investigator (i.e.,
             homeless, non-compliant, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon R Bernard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon D Truwit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Cone</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Veterans Health Care System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <results_first_submitted>January 8, 2016</results_first_submitted>
  <results_first_submitted_qc>February 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2016</results_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Gordon Bernard</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>CAP</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study stopped before dosing completed</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality</title>
        <description>death during 90 day study period</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>death during 90 day study period</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total enrollment only 25 patients and the study was terminated early due to low enrollment. No further statistical analysis was done.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shock Free Days</title>
        <description>Not requiring pressor support for hypotension</description>
        <time_frame>15 days</time_frame>
        <population>2 participants from the Ticagrelor arm and 1 from the placebo arm died during the 15 day period</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Shock Free Days</title>
          <description>Not requiring pressor support for hypotension</description>
          <population>2 participants from the Ticagrelor arm and 1 from the placebo arm died during the 15 day period</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.58" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="11.54" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Free Days</title>
        <time_frame>29 days</time_frame>
        <population>2 participants from each arm died during the 29 day period</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Free Days</title>
          <population>2 participants from each arm died during the 29 day period</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.16" lower_limit="16" upper_limit="29"/>
                    <measurement group_id="O2" value="22.3" lower_limit="14" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Mortality</title>
        <description>Did the patient die during the hospitalization?</description>
        <time_frame>Throughout hospitalization (About 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Mortality</title>
          <description>Did the patient die during the hospitalization?</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Free Days</title>
        <description>Number of days the patient is not in the hospital</description>
        <time_frame>29 days</time_frame>
        <population>2 participants from each group died during this time period</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Free Days</title>
          <description>Number of days the patient is not in the hospital</description>
          <population>2 participants from each group died during this time period</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.16" lower_limit="3" upper_limit="22"/>
                    <measurement group_id="O2" value="16.53" lower_limit="2" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <description>Did the patient develop a stroke during the 90 day study?</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>Did the patient develop a stroke during the 90 day study?</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke, Myocardial Infarct, Mortality</title>
        <description>number of participants that suffered stroke, myocardial infarct, mortality</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke, Myocardial Infarct, Mortality</title>
          <description>number of participants that suffered stroke, myocardial infarct, mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>Did the patient have a myocardial infarction during the 90 day study?</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>Did the patient have a myocardial infarction during the 90 day study?</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Initiation of Unassisted Breathing</title>
        <description>Only in patients on mechanical ventilation and assuming patient achieves 48 consecutive hours of unassisted breathing</description>
        <time_frame>29 days</time_frame>
        <population>2 participants from each arm died during this period</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initiation of Unassisted Breathing</title>
          <description>Only in patients on mechanical ventilation and assuming patient achieves 48 consecutive hours of unassisted breathing</description>
          <population>2 participants from each arm died during this period</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.9" lower_limit="49.5" upper_limit="310.5"/>
                    <measurement group_id="O2" value="173.19" lower_limit="46.65" upper_limit="404.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Need for Re-instituting Assisted or Mechanical Ventilation After Achieving 48 Consecutive Hours of Unassisted Breathing or Comfort Care Chosen (Withdrawal of Support)</title>
        <time_frame>90 days</time_frame>
        <population>only participants that required mechanical ventilation</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Re-instituting Assisted or Mechanical Ventilation After Achieving 48 Consecutive Hours of Unassisted Breathing or Comfort Care Chosen (Withdrawal of Support)</title>
          <population>only participants that required mechanical ventilation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Need for Dialysis</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Dialysis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ICU Length of Stay</title>
        <description>Includes ICU readmission if during same hospital stay</description>
        <time_frame>29 days</time_frame>
        <population>2 participants from each arm died during this period</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <description>Includes ICU readmission if during same hospital stay</description>
          <population>2 participants from each arm died during this period</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="O2" value="8.77" lower_limit="2" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospital Length of Stay</title>
        <description>In days</description>
        <time_frame>29 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>In days</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O2" value="12.46" lower_limit="4" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Discharge Disposition</title>
        <description>(Home, other facility, with or without assisted ventilation)</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Discharge Disposition</title>
          <description>(Home, other facility, with or without assisted ventilation)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Home</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extended Care without Ventilator</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extended Care with Ventilator</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>In patient rehabilitation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death prior to discharge</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Ticagrelor: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Placebo: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Type II MI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Complicated Para-pneumonic Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis-Right Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukemoid Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>vaginal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hematoma on forearm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gordon Bernard, Professor of Medicine, Associate Vice Chancellor for Research</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-343-0077</phone>
      <email>gordon.bernard@Vanderbilt.Edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

